Stockscreener 앱 받기
62.11
0.67%
-0.42
시간 외 거래:
60.00
-2.11
-3.40%
Incyte Corp 주식(INCY)의 최신 뉴스
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte to Present at Upcoming Investor Conference - Business Wire
9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga
Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus
Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus
Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus
Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com
BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey
Incyte: Q1 Earnings Snapshot - CT Insider
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com
BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace
Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus
Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com
Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus
Incyte Q1 Results Top Estimates - Nasdaq
Incyte earnings beat by $0.12, revenue topped estimates - Investing.com
Incyte Reports 2025 First Quarter Financial Results - TradingView
Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus
Incyte (INCY) Q1 Earnings Report Preview: What To Look For - Barchart.com
Incyte to Highlight Early-Stage Oncology Data at American Associ - GuruFocus
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
4Q24 earnings stir biopharma stocks, leading to mixed performance - BioWorld MedTech
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - BioSpace
Incyte to Showcase New Data from its Oncology Portfolio at 2025 - GuruFocus
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know - Yahoo Finance
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Cytokine Release Syndrome Treatment Market Size in 7MM - openPR.com
Incyte (INCY) Sees Boosted Price Target by BofA Analyst | INCY Stock News - GuruFocus
Lobbying Update: $60,000 of INCYTE CORPORATION lobbying was just disclosed - Nasdaq
Incyte Grants Restricted Stock Units to New Employees - MSN
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
0.39%
3.66%
자본화:
|
볼륨(24시간):